The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension

Raymond L. Benza, Mardi Gomberg-Maitland, Dave P. Miller, Adaani Frost, Robert Frantz, Aimee J. Foreman, David B. Badesch, Michael D. McGoon

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Background: In pulmonary arterial hypertension (PAH), survival predictions can be important for optimization of therapeutic strategies. The present study aimed to validate a quantitative algorithm for predicting survival derived from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) and develop a simplified calculator for everyday clinical use. Methods: Prospectively collected data from patients with newly diagnosed (< 3 months) World Health Organization group I pulmonary hypertension enrolled in the REVEAL Registry were used to validate a predictive algorithm for 1-year survival. Model calibration was evaluated by comparing algorithm-predicted survival with observed Kaplan-Meier estimates for the overall validation cohort and for five risk groups. Similarly, the risk discriminators for the simplified calculator were compared with those of the quantitative algorithm. Results: The validation cohort comprised 504 individuals with mean ± SD 6-min walk distance 308 ± 128 m, and 61.5% were functional class III. The proportion of patients surviving 1 year fell within the range predicted by the model (95.1%, 91.5%, 84.6%, 76.3%, and 58.2%, respectively) among patients in the low (predicted survival ≥ 95%), average (90% to < 95%), moderate (85% to < 90%), high (70% to < 85%), and very high (< 70%) risk strata. Predicted and observed 1-year survival were similar across risk stratum, and the c-index indicated good discrimination for both the full equation (0.726) and the simplified risk calculator (0.724). Conclusions: The REVEAL Registry predictive algorithm and simplified risk score calculator are well calibrated and demonstrate good discriminatory ability in patients with newly or previously diagnosed PAH. Trial registry: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

Original languageEnglish (US)
Pages (from-to)354-362
Number of pages9
JournalChest
Volume141
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Pulmonary Hypertension
Registries
Survival
Kaplan-Meier Estimate
Disease Management
Calibration

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Benza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R., Foreman, A. J., ... McGoon, M. D. (2012). The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest, 141(2), 354-362. https://doi.org/10.1378/chest.11-0676

The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. / Benza, Raymond L.; Gomberg-Maitland, Mardi; Miller, Dave P.; Frost, Adaani; Frantz, Robert; Foreman, Aimee J.; Badesch, David B.; McGoon, Michael D.

In: Chest, Vol. 141, No. 2, 02.2012, p. 354-362.

Research output: Contribution to journalArticle

Benza, RL, Gomberg-Maitland, M, Miller, DP, Frost, A, Frantz, R, Foreman, AJ, Badesch, DB & McGoon, MD 2012, 'The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension', Chest, vol. 141, no. 2, pp. 354-362. https://doi.org/10.1378/chest.11-0676
Benza, Raymond L. ; Gomberg-Maitland, Mardi ; Miller, Dave P. ; Frost, Adaani ; Frantz, Robert ; Foreman, Aimee J. ; Badesch, David B. ; McGoon, Michael D. / The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. In: Chest. 2012 ; Vol. 141, No. 2. pp. 354-362.
@article{ea659315e4524051abe3f5507482d977,
title = "The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension",
abstract = "Background: In pulmonary arterial hypertension (PAH), survival predictions can be important for optimization of therapeutic strategies. The present study aimed to validate a quantitative algorithm for predicting survival derived from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) and develop a simplified calculator for everyday clinical use. Methods: Prospectively collected data from patients with newly diagnosed (< 3 months) World Health Organization group I pulmonary hypertension enrolled in the REVEAL Registry were used to validate a predictive algorithm for 1-year survival. Model calibration was evaluated by comparing algorithm-predicted survival with observed Kaplan-Meier estimates for the overall validation cohort and for five risk groups. Similarly, the risk discriminators for the simplified calculator were compared with those of the quantitative algorithm. Results: The validation cohort comprised 504 individuals with mean ± SD 6-min walk distance 308 ± 128 m, and 61.5{\%} were functional class III. The proportion of patients surviving 1 year fell within the range predicted by the model (95.1{\%}, 91.5{\%}, 84.6{\%}, 76.3{\%}, and 58.2{\%}, respectively) among patients in the low (predicted survival ≥ 95{\%}), average (90{\%} to < 95{\%}), moderate (85{\%} to < 90{\%}), high (70{\%} to < 85{\%}), and very high (< 70{\%}) risk strata. Predicted and observed 1-year survival were similar across risk stratum, and the c-index indicated good discrimination for both the full equation (0.726) and the simplified risk calculator (0.724). Conclusions: The REVEAL Registry predictive algorithm and simplified risk score calculator are well calibrated and demonstrate good discriminatory ability in patients with newly or previously diagnosed PAH. Trial registry: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.",
author = "Benza, {Raymond L.} and Mardi Gomberg-Maitland and Miller, {Dave P.} and Adaani Frost and Robert Frantz and Foreman, {Aimee J.} and Badesch, {David B.} and McGoon, {Michael D.}",
year = "2012",
month = "2",
doi = "10.1378/chest.11-0676",
language = "English (US)",
volume = "141",
pages = "354--362",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension

AU - Benza, Raymond L.

AU - Gomberg-Maitland, Mardi

AU - Miller, Dave P.

AU - Frost, Adaani

AU - Frantz, Robert

AU - Foreman, Aimee J.

AU - Badesch, David B.

AU - McGoon, Michael D.

PY - 2012/2

Y1 - 2012/2

N2 - Background: In pulmonary arterial hypertension (PAH), survival predictions can be important for optimization of therapeutic strategies. The present study aimed to validate a quantitative algorithm for predicting survival derived from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) and develop a simplified calculator for everyday clinical use. Methods: Prospectively collected data from patients with newly diagnosed (< 3 months) World Health Organization group I pulmonary hypertension enrolled in the REVEAL Registry were used to validate a predictive algorithm for 1-year survival. Model calibration was evaluated by comparing algorithm-predicted survival with observed Kaplan-Meier estimates for the overall validation cohort and for five risk groups. Similarly, the risk discriminators for the simplified calculator were compared with those of the quantitative algorithm. Results: The validation cohort comprised 504 individuals with mean ± SD 6-min walk distance 308 ± 128 m, and 61.5% were functional class III. The proportion of patients surviving 1 year fell within the range predicted by the model (95.1%, 91.5%, 84.6%, 76.3%, and 58.2%, respectively) among patients in the low (predicted survival ≥ 95%), average (90% to < 95%), moderate (85% to < 90%), high (70% to < 85%), and very high (< 70%) risk strata. Predicted and observed 1-year survival were similar across risk stratum, and the c-index indicated good discrimination for both the full equation (0.726) and the simplified risk calculator (0.724). Conclusions: The REVEAL Registry predictive algorithm and simplified risk score calculator are well calibrated and demonstrate good discriminatory ability in patients with newly or previously diagnosed PAH. Trial registry: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

AB - Background: In pulmonary arterial hypertension (PAH), survival predictions can be important for optimization of therapeutic strategies. The present study aimed to validate a quantitative algorithm for predicting survival derived from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) and develop a simplified calculator for everyday clinical use. Methods: Prospectively collected data from patients with newly diagnosed (< 3 months) World Health Organization group I pulmonary hypertension enrolled in the REVEAL Registry were used to validate a predictive algorithm for 1-year survival. Model calibration was evaluated by comparing algorithm-predicted survival with observed Kaplan-Meier estimates for the overall validation cohort and for five risk groups. Similarly, the risk discriminators for the simplified calculator were compared with those of the quantitative algorithm. Results: The validation cohort comprised 504 individuals with mean ± SD 6-min walk distance 308 ± 128 m, and 61.5% were functional class III. The proportion of patients surviving 1 year fell within the range predicted by the model (95.1%, 91.5%, 84.6%, 76.3%, and 58.2%, respectively) among patients in the low (predicted survival ≥ 95%), average (90% to < 95%), moderate (85% to < 90%), high (70% to < 85%), and very high (< 70%) risk strata. Predicted and observed 1-year survival were similar across risk stratum, and the c-index indicated good discrimination for both the full equation (0.726) and the simplified risk calculator (0.724). Conclusions: The REVEAL Registry predictive algorithm and simplified risk score calculator are well calibrated and demonstrate good discriminatory ability in patients with newly or previously diagnosed PAH. Trial registry: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

UR - http://www.scopus.com/inward/record.url?scp=84863011141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863011141&partnerID=8YFLogxK

U2 - 10.1378/chest.11-0676

DO - 10.1378/chest.11-0676

M3 - Article

VL - 141

SP - 354

EP - 362

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -